The Three-year Underlying Earnings Growth at Aier Eye Hospital Group (SZSE:300015) Is Promising, but the Shareholders Are Still in the Red Over That Time
The Three-year Underlying Earnings Growth at Aier Eye Hospital Group (SZSE:300015) Is Promising, but the Shareholders Are Still in the Red Over That Time
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long term Aier Eye Hospital Group Co., Ltd. (SZSE:300015) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 70% decline in the share price in that time. And the ride hasn't got any smoother in recent times over the last year, with the price 49% lower in that time. Shareholders have had an even rougher run lately, with the share price down 18% in the last 90 days. However, one could argue that the price has been influenced by the general market, which is down 9.2% in the same timeframe.
如果您正在構建一個適當分散的股票投資組合,那麼其中一些選擇將表現不佳。 長揸愛爾眼科(Aier Eye Hospital Group Co., Ltd.)(SZSE:300015)的股東們深知這一點,因爲股價在三年內大幅下跌。不幸的是,他們在此期間經歷了股價下跌70%。 最近一年的時候,價格下跌了49%,而這種震盪並沒有變得更加順利。 股東們最近的經歷甚至更加艱難,股價在過去90天內下跌了18%。不過,有人可能會認爲,價格受到了股市的影響,而股市在同一時間範圍內下跌了9.2%。
If the past week is anything to go by, investor sentiment for Aier Eye Hospital Group isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
如果過去一週的投資者情緒表明,愛爾眼科並不樂觀,那麼我們就要看看基本面和股價之間是否存在不匹配。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
市場有時候是有效的,但價格並不總是反映公司的基本業務表現。通過比較每股收益和股價變化,我們可以了解投資者對公司的看法如何隨着時間變化而變化。
During the unfortunate three years of share price decline, Aier Eye Hospital Group actually saw its earnings per share (EPS) improve by 16% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.
在不幸的三年股價下跌期間,愛爾眼科每股收益(EPS) 實際上每年增長16%。鑑於股價反應,人們可能會懷疑EPS不是該時期業務績效的良好指南(可能是由於一次性損失或收益)。否則,公司曾經被過度炒作,因此其增長令人失望。
It's worth taking a look at other metrics, because the EPS growth doesn't seem to match with the falling share price.
值得關注其他指標,因爲EPS增長似乎與股價下跌不符。
The modest 1.5% dividend yield is unlikely to be guiding the market view of the stock. Revenue is actually up 13% over the three years, so the share price drop doesn't seem to hinge on revenue, either. This analysis is just perfunctory, but it might be worth researching Aier Eye Hospital Group more closely, as sometimes stocks fall unfairly. This could present an opportunity.
適度的1.5%股息率不太可能引導股市對該股的看法。 其實在三年內,營業收入實際上增長了13%,所以股價下跌似乎並不取決於營業收入。 這只是一個簡單的分析,但認真研究愛爾眼科可能是值得的,因爲有時股票會不公平地下跌。這可能帶來機會。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240728/0-84ffe44e0c5cb9ade588ebf75d481312-0-b38ac96eeddab4be778c8a2ec78f583b.png/big)
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. You can see what analysts are predicting for Aier Eye Hospital Group in this interactive graph of future profit estimates.
我們很高興地報告,CEO的薪酬比大多數同等資本化公司的CEO都要低。 但是,雖然值得檢查CEO的薪酬,但真正重要的問題是公司能否在未來增長收益。您可以在未來利潤預測的交互式圖表中查看分析師對愛爾眼科的預測。
A Different Perspective
不同的觀點
We regret to report that Aier Eye Hospital Group shareholders are down 48% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 19%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 0.2% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Aier Eye Hospital Group has 1 warning sign we think you should be aware of.
不幸的是,愛爾眼科的股東們在今年下跌了48%(包括股息)。 不幸的是,這比19%的整體市場下跌更糟糕。 儘管如此,在下跌市場中一些股票被拋售是不可避免的。 關鍵是要關注基本發展。不幸的是,去年的表現總結了一段糟糕的時期,股東在過去五年中每年面臨着總損失0.2%。 我認爲長期觀察股價作爲業績的一種代理非常有趣。 但要真正獲得深入的見解,我們需要考慮其他信息。 比如說,承擔風險-愛爾眼科有一個警告信號,我們認爲您應該了解。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果您願意查看另一家公司(具有潛在的更好財務狀況),請不要錯過這個免費的公司列表,證明它們可以增長收益。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。